Status:
COMPLETED
Prognostic Biomarkers in Patients With Endometrial Cancer
Lead Sponsor:
Gynecologic Oncology Group
Collaborating Sponsors:
National Cancer Institute (NCI)
Conditions:
Endometrial Adenocarcinoma
Recurrent Uterine Corpus Carcinoma
Eligibility:
FEMALE
Brief Summary
This research study is studying prognostic biomarkers in tissue samples from patients with endometrial cancer. Studying samples of tissue from patients with cancer in the laboratory may help doctors l...
Detailed Description
PRIMARY OBJECTIVES: I. To validate the clinicopathologic associations and prognostic significance of ATR mutation in endometrioid endometrial cancer cases with defective DNA mismatch repair. OUTLINE...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Women who were eligible and evaluable for the GOG-0210 molecular staging protocol in women with endometrial cancer
- Women who were registered during the unrestricted enrollment period (through 9/23/07) will automatically qualify
- Women who were registered during the restricted enrollment period (after 9/23/07) will only be considered if needed
- Women who had histologically confirmed endometrioid endometrial adenocarcinoma regardless of stage or grade
- Women who have defective DNA mismatch repair and are microsatellite instability positive (MSI+ and MSI-low)
- Women who consented to allow their specimens and clinical data to be used for future cancer research
- Women who have sufficient high-quality genomic DNA from tumor available for mutation analysis of ATR
Exclusion
Key Trial Info
Start Date :
September 1 2010
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
Estimated Enrollment :
2824 Patients enrolled
Trial Details
Trial ID
NCT01208467
Start Date
September 1 2010
Last Update
August 23 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Gynecologic Oncology Group
Philadelphia, Pennsylvania, United States, 19103